SafetyTolerability and efficacy of rivastigmine in Taiwanese patients with alzheimers disease: A prospective post-marketing surveillance study

Clinical Drug Investigation

Volumn 29, Issue 11, 2009, Pages 729-738

  Chiu, Pai Yi ^a,b,j   Dai, Dao En ^c   Hsu, Hai Pei ^d   Lee, Chao ^e   Lin, Juei Jueng ^f   Kuo, Hung Chou ^g   Huang, Ying Chih ^h   Liu, Yung Chang ⁱ   Tsai, Ching Piao ^j,k  

^a LIN SHIN HOSPITAL   (Taiwan)

^b Central Taichung Technical and Science University   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d St Pauls Hospital   (Taiwan)

^e JEN AI HOSPITAL   (Taiwan)

^f Chu Shang Show Chwan Hospital   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

ⁱ CHENG CHING GENERAL HOSPITAL   (Taiwan)

^j TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^k TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL DEMENTIA SCALE; CLINICAL TRIAL; COGNITION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RATING SCALE; TAIWAN; VOMITING; MIDDLE AGED;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHENYLCARBAMATES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 70350055472     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11315320-000000000-00000     Document Type: Article

References (17)

1. Graves AB, Kukull WA. The epidemiology of dementia. In: Morris JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker, 1994: 23-69
2. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999; 12: 307-323
3. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
5. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318: 633-640
6. Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-477
7. Plosker GL, Keating GM. Management ofmild to moderate Alzheimer disease: defining the role of rivastigmine. Dis Manage Health Outcomes 2004; 12: 55-72
8. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397
9. Grossberg G, Irwin P, Satlin A, et al. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 2004; 12: 420-431
10. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trials. Lancet Neurol 2007; 6: 782-792
11. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008; 179: 1019-1026
12. Sikdar S. Should titration schedules for cholinesterase inhibitors be changed? Int J Geriatr Psychiatry 2003; 18: 1063-1064
13. Farlow M, Anand R, Messina Jr J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 234-241
14. Potkin SG, Anand R, Hartman R, et al. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 713-720
15. Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004; 20: 1747-1752
16. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset al.zheimer's disease: therapeutic implications. Age Ageing 2003; 32: 200-204
17. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 2000; 16: 199-226 (Pubitemid 30166921)